^
    Back
    Association details:
    Biomarker:PD-L1 overexpression + TMB-H
    Cancer:Anal Carcinoma
    Drug Class:EGFR inhibitor +
    Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2022
    Title:

    Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study.

    Published date:
    01/18/2022
    Excerpt:
    When combined together and with high TILs, high TMB and PD-L1 identified pts with significantly better prognosis in OS (HR=0.43; 95% CI=0.21-0.87; p=0.019) and PFS (HR=0.48; 95%CI=0.23-1.00; p=0.051). Remarkable responses were also observed in pts with high PD-L1 expression and TMB....TranslaCARACAS study documented prognostic role of high TMB and PD-L1 in mSCAC treated with ICI with or without anti-EGFR.
    Trial ID:
    CARACAS